Cargando…

Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2

The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a stru...

Descripción completa

Detalles Bibliográficos
Autores principales: Taşlı, Neslihan Pakize, Gönen, Zeynep Burçin, Kırbaş, Oğuz Kaan, Gökdemir, Nur Seda, Bozkurt, Batuhan Turhan, Bayrakcı, Buse, Sağraç, Derya, Taşkan, Ezgi, Demir, Sevda, Ekimci Gürcan, Nur, Bayındır Bilgiç, Melike, Bayrak, Ömer Faruk, Yetişkin, Hazel, Kaplan, Büşra, Pavel, Shaikh Terkıs Islam, Dinç, Gökçen, Serhatlı, Müge, Çakırca, Gamze, Eken, Ahmet, Aslan, Vedat, Yay, Mehmet, Karakukcu, Musa, Unal, Ekrem, Gül, Fethi, Basaran, Kemal Erdem, Ozkul, Yusuf, Şahin, Fikrettin, Jones, Olcay Y., Tekin, Şaban, Özdarendeli, Aykut, Cetin, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987587/
https://www.ncbi.nlm.nih.gov/pubmed/35401544
http://dx.doi.org/10.3389/fimmu.2022.824378
Descripción
Sumario:The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.